Articles

Permanent URI for this collection

https://ir.knust.edu.gh/handle/123456789/70

Browse

Browsing Articles by Author "0000-0001-5589-9357"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Platelet-rich plasma for treating dry eye disease – A systematic review and meta-analysis
    (Contact Lens and Anterior Eye, 2024-02) Akowuah, Prince Kwaku; Obinwanne, Chukwuemeka Junior; Owusu, Ebenezer; Kyeremeh, Sylvester; Bonsu, Kwaku; Karikari, Lucy Akua Afriyie; Akomeah, Felicia Akyaa; Nkansah, Ernest Kyei; Kobiah-Acquah, Emmanuel; 0000-0003-3657-6768; 0000-0001-5589-9357; 0000-0003-1612-4350; 0000-0002-7916-0175; 0009-0000-1033-7596; 0009-0006-7208-3513; 0000-0002-3803-7218; 0000-0002-5955-7992
    Purpose Dry eye disease has public health and economic significance. Platelet-rich plasma is rich in anti-inflammatory agents and growth factors, both beneficial for ocular surface repair. This study aimed to conduct a systematic review and meta-analysis to summarize the benefits of platelet-rich plasma for treating dry eye disease and its adverse effects. Methods Prospective comparative studies using platelet-rich plasma as monotherapy for dry eye disease were included for efficacy assessment. Before-after studies were included for adverse events assessment. Data sources included PubMed, Google Scholar, Web of Science, and Scopus. A systematic review and meta-analysis protocol was pre-registered on PROSPERO (CRD42022347982). PRISMA guidelines were followed. The National Health Institute (NIH) quality assessment tool for before-after studies, the Cochrane risk of bias tool (RoB2), and the methodological index for non-randomized studies were used to assess the risk of bias. Heterogeneity was assessed using the I2 statistic. Results 19 studies (10 comparative and 9 before-after) were included in the systematic review and meta-analysis. The occurrence rate of adverse effects was 2.6 % (95 % CI: 0.5 – 4.7). The pooled standardized mean difference (SMD) for dry eye symptoms was 0.81 (95 % CI: 0.25 – 1.37; I2 = 82 %; p < 0.00001; Z = 2.84, p = 0.004); tear quality was 0.44 (95 % CI: 0.06 – 0.81; I2 = 67 %; p = 0.003; Z = 2.26, p = 0.02); tear quantity was 0.45 (95 % CI: 0.03 – 0.88; I2 = 74 %; p = 0.0003; Z = 2.10, p = 0.04); and corneal staining 0.72 (95 % CI: 0.14 – 1.30; I2 = 85 %; p < 0.00001; Z = 2.43, p = 0.02). Conclusion The current study shows that platelet-rich plasma is efficacious in managing dry eye disease, significantly reducing dry eye signs and symptoms. Such significant improvements could translate to improved quality of life.